TTM
−$52.66M
YoY change
+96.8%
5Y CAGR
—
Peak year (2019)
−$4.70M
Cumulative EBITDA
−$248.10M
EBITDA history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: −$59.75M
EBITDA growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: +96.8%
EBITDA history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | −$59.75M | +96.8% | −$29.39M | ||
| 2024 | −$30.36M | -13.5% | +$4.76M | ||
| 2023 | −$35.12M | -22.4% | +$10.13M | ||
| 2022 | −$45.24M | -4.7% | +$2.24M | ||
| 2021 | −$47.48M | +303.5% | −$35.71M | ||
| 2020 | −$11.77M | +150.6% | −$7.07M | ||
| 2019 | −$4.70M | — | — |
- 2025−$59.75M+96.8%
- 2024−$30.36M-13.5%
- 2023−$35.12M-22.4%
- 2022−$45.24M-4.7%
- 2021−$47.48M+303.5%
- 2020−$11.77M+150.6%
- 2019−$4.70M—
EBITDA values are taken from Climb Bio's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Climb Bio (CLYM)
According to Climb Bio's latest reported financial statements, the company's current EBITDA (TTM) is −$52.66M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Climb Bio (CLYM) most recent annual EBITDA stands at −$59.75M (2025) – surged 96.8% year-over-year.
−$4.70M stands as the all-time-high annual EBITDA, posted in 2019, against a low of −$59.75M during 2025.
Climb Bio EBITDA by Year
Climb Bio EBITDA 2025: −$59.75M
2025's EBITDA for Climb Bio came in at −$59.75M, surged 96.8% from 2024. This figure represents the lowest annual value in the available history.
Climb Bio EBITDA 2024: −$30.36M
Climb Bio posted EBITDA of −$30.36M in 2024, declined 13.5% below 2023.
Climb Bio EBITDA 2023: −$35.12M
In 2023, Climb Bio reported EBITDA of −$35.12M, declined 22.4% below 2022.
Climb Bio EBITDA 2022: −$45.24M
Climb Bio EBITDA in 2022 was −$45.24M, edged down 4.7% below 2021.
Climb Bio EBITDA 2021: −$47.48M
Climb Bio EBITDA in 2021 was −$47.48M.
See more financial history for Climb Bio (CLYM).
Sector peers by EBITDA
Healthcare peers of Climb Bio (CLYM), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation